Literature DB >> 32735313

Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony.

Robert M Califf1, Adrian F Hernandez2,3, Martin Landray4.   

Abstract

Mesh：

Year:  2020        PMID： 32735313     DOI： 10.1001/jama.2020.13319

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  14 in total

1.  Self-experimentation, ethics, and regulation of vaccines.

Authors:  Christi J Guerrini; Jacob S Sherkow; Michelle N Meyer; Patricia J Zettler
Journal:  Science       Date:  2020-09-17       Impact factor: 47.728

2.  Making trials part of good clinical care: lessons from the RECOVERY trial.

Authors:  Guilherme Pessoa-Amorim; Mark Campbell; Lucy Fletcher; Peter Horby; Martin Landray; Marion Mafham; Richard Haynes
Journal:  Future Healthc J       Date:  2021-07

3.  Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Authors:  Jessica M Franklin; Elisabetta Patorno; Rishi J Desai; Robert J Glynn; David Martin; Kenneth Quinto; Ajinkya Pawar; Lily G Bessette; Hemin Lee; Elizabeth M Garry; Nileesa Gautam; Sebastian Schneeweiss
Journal:  Circulation       Date:  2020-12-17       Impact factor: 29.690

4.  When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?

Authors:  Gregory E Simon; Richard Platt; Jonathan H Watanabe; Andrew B Bindman; Alex John London; Michael Horberg; Adrian Hernandez; Robert M Califf
Journal:  Clin Pharmacol Ther       Date:  2021-05-19       Impact factor: 6.903

Review 5.  When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?

Authors:  Jessica M Franklin; Richard Platt; Nancy A Dreyer; Alex John London; Gregory E Simon; Jonathan H Watanabe; Michael Horberg; Adrian Hernandez; Robert M Califf
Journal:  Clin Pharmacol Ther       Date:  2021-05-09       Impact factor: 6.903

6.  Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centers.

Authors:  Subha Madhavan; Lisa Bastarache; Jeffrey S Brown; Atul J Butte; David A Dorr; Peter J Embi; Charles P Friedman; Kevin B Johnson; Jason H Moore; Isaac S Kohane; Philip R O Payne; Jessica D Tenenbaum; Mark G Weiner; Adam B Wilcox; Lucila Ohno-Machado
Journal:  J Am Med Inform Assoc       Date:  2021-02-15       Impact factor: 4.497

7.  How severe COVID-19 infection is changing ARDS management.

Authors:  Niall D Ferguson; Tài Pham; Michelle Ng Gong
Journal:  Intensive Care Med       Date:  2020-09-18       Impact factor: 17.440

8.  Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country.

Authors:  Geert Molenberghs; Marc Buyse; Steven Abrams; Niel Hens; Philippe Beutels; Christel Faes; Geert Verbeke; Pierre Van Damme; Herman Goossens; Thomas Neyens; Sereina Herzog; Heidi Theeten; Koen Pepermans; Ariel Alonso Abad; Ingrid Van Keilegom; Niko Speybroeck; Catherine Legrand; Stefanie De Buyser; Frank Hulstaert
Journal:  Contemp Clin Trials       Date:  2020-10-22       Impact factor: 2.226

9.  What cannabis can learn from Covid: Hydroxychloroquine research suggests the next step for medical cannabis research.

Authors:  Theodore L Caputi
Journal:  Int J Drug Policy       Date:  2021-01-29

Review 10.  Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.

Authors:  Stephen A Klassen; Jonathon W Senefeld; Katherine A Senese; Patrick W Johnson; Chad C Wiggins; Sarah E Baker; Noud van Helmond; Katelyn A Bruno; Liise-Anne Pirofski; Shmuel Shoham; Brenda J Grossman; Jeffrey P Henderson; R Scott Wright; DeLisa Fairweather; Nigel S Paneth; Rickey E Carter; Arturo Casadevall; Michael J Joyner
Journal:  Front Med (Lausanne)       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.